Please provide us with a few details so that we can match you with the right expert in your field.
*Required
Despite extensive preclinical testing, most drugs fail in clinical trials, either due to a lack of efficacy or to unacceptable levels of toxicity. This is largely caused by the historical reliance on preclinical models that do not accurately reflect human physiology. This realisation is driving the current transition towards human-relevant in vitro models, such as iPSC-derived cell cultures, for drug discovery and toxicity screening.
We can help you harness the power of human iPSC-derived cell models to accelerate and de-risk your drug discovery journey. If you wish to obtain translational human pre-clinical data from cell types that are difficult to access and culture directly from primary tissue, such as CNS cells, or are looking to reduce your reliance on in vivo models for your safety and efficacy testing, human iPSC-derived cells can be the right solution.
Our team can help you accelerate your project to clinic: talk directly to an expert about your specific needs.